Pharmaceutical compositions comprising meloxicam
View Patent ↗Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as arthritis.
1. A method of treating arthritis comprising: orally administering a solid dosage form once daily to a human being suffering from arthritis, wherein the solid dosage form comprises: 1) a complex of meloxicam and a sulfobutyl ether β-cyclodextrin (SBEβCD), and 2) a bicarbonate, wherein orally administering the solid dosage form to the human being results in a T max of meloxicam that is shorter than a T max of a reference solid dosage form that: 1) contains the same amount of meloxicam, 2) does not contain an SBEβCD, and 3) does not contain a bicarbonate, wherein the solid dosage form has been shown to have a median T max of meloxicam that is less than 2 hours in human subjects.
2. The method of claim 1 , wherein the solid dosage form contains about 10 mg to about 20 mg of meloxicam.
3. The method of claim 1 , wherein the solid dosage form contains about 15 mg of meloxicam.
4. The method of claim 1 , wherein the SBEβCD has about 6 to about 7 sulfobutyl ether groups for each molecule of β-cyclodextrin.
5. The method of claim 1 , wherein the solid dosage form contains about 50 mg to about 200 mg of the SBEβCD.
6. The method of claim 1 , wherein the solid dosage form contains about 100 mg of the SBEβCD.
7. The method of claim 1 , wherein the solid dosage form contains about 400 mg to about 600 mg of the bicarbonate.
8. The method of claim 7 , wherein the solid dosage form contains about 500 mg of sodium bicarbonate.
9. The method of claim 1 , wherein the solid dosage form further comprises a proton pump inhibitor.
10. The method of claim 9 , wherein the proton pump inhibitor is esomeprazole.
11. The method of claim 10 , wherein about 30 mg to about 50 mg of esomeprazole is present in the solid dosage form.
12. The method of claim 1 , wherein the solid dosage form is administered daily under fasting condition for at least 6 days.
13. The method of claim 1 , wherein the human being is suffering from osteoarthritis or rheumatoid arthritis.
14. The method of claim 1 , wherein the human being is being treated with another pain medication before the solid dosage form comprising meloxicam is orally administered, and wherein the use of another pain medication is reduced by at least about 15% after administration of the solid dosage form.
15. A method of treating arthritis comprising: orally administering a solid dosage form once daily to a human being suffering from arthritis, wherein the solid dosage form comprises: 1) a complex of meloxicam and a sulfobutyl ether β-cyclodextrin (SBEβCD), and 2) a bicarbonate, wherein orally administering the solid dosage form to the human being results in a C max of meloxicam that is at least about 30% higher than a C max of a reference solid dosage form that: 1) contains the same amount of meloxicam, 2) does not contain an SBEβCD, and 3) does not contain a bicarbonate.
16. The method of claim 15 , wherein the solid dosage form contains about 10 mg to about 20 mg of meloxicam.
17. The method of claim 15 , wherein the solid dosage form contains about 15 mg of meloxicam.
18. The method of claim 15 , wherein the SBEβCD has about 6 to about 7 sulfobutyl ether groups for each molecule of β-cyclodextrin.
19. The method of claim 15 , wherein the solid dosage form contains about 50 mg to about 200 mg of the SBEβCD.
20. The method of claim 15 , wherein the solid dosage form contains about 100 mg of the SBEβCD.
21. The method of claim 15 , wherein the solid dosage form contains about 400 mg to about 600 mg of the bicarbonate.
22. The method of claim 21 , wherein the solid dosage form contains about 500 mg of sodium bicarbonate.
23. The method of claim 15 , wherein the solid dosage form further comprises an acid inhibitor.
24. The method of claim 23 , wherein the acid inhibitor is a proton pump inhibitor.
25. The method of claim 24 , wherein the proton pump inhibitor is esomeprazole.
26. The method of claim 25 , wherein about 30 mg to about 50 mg of esomeprazole is present in the solid dosage form.
27. The method of claim 15 , wherein the solid dosage form is administered daily under fasting condition.
28. The method of claim 15 , wherein the human being is suffering from osteoarthritis or rheumatoid arthritis.
29. The method of claim 15 , wherein the human being is being treated with another pain medication before the solid dosage form comprising meloxicam is orally administered, and wherein the use of another pain medication is reduced by at least about 15% after administration of the solid dosage form.
30. The method of claim 15 , wherein the solid dosage form is administered daily under fasting condition for at least 6 days.